WVE WAVE Life Sciences

Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020

Wave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 9, 2020, to discuss its third quarter 2020 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at . The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 3563968. Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit and follow Wave on Twitter @WaveLifeSci.

Investor Contacts:

Kate Rausch

617-949-4827

Graham Morrell

781-686-9600

Media Contact:

Alicia Suter

617-949-4817

EN
26/10/2020

Underlying

WVEWAVE Life Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

 PRESS RELEASE
Free
WVE WAVE Life Scien...

Wave Life Sciences to Present at Upcoming Investor Conferences

Wave Life Sciences to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in November. Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Tuesday, November 11, 2025 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside ch...

November 7, 2025 1 EN
 PRESS RELEASE
Free
WVE WAVE Life Scien...

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic ...

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025 Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing In preclinical models, INHBE GalNAc-siRNA led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue, supporting potential for metabolic improvement ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
WVE WAVE Life Scien...

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for ...

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025 CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025, to review the company’s third quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the...

November 4, 2025 1 EN
 PRESS RELEASE
Free
WVE WAVE Life Scien...

Correcting and Replacing Wave Life Sciences Announced Positive Target ...

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.” Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
WVE WAVE Life Scien...

Wave Life Sciences Announced Positive Target Engagement Data from INLI...

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date Activin E reduction in lowest dose cohort of INLIGHT was sustained through 6 months, supporting once or twice a year dosing Multiple clinical data updates from INLIGHT, including body composition and body weight, are ...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch